Celgene GmbH: Improving the lives of patients worldwide

Celgene is a globally active biopharmaceutical company that was founded in 1986. Celgene engages in the research, development and commercialization of innovative medicines, mainly for the treat­ment of various forms of cancer and diseases of the immune system. In particular, our company addresses the challenge of developing new treatments for rare diseases.

Celgene GmbH, based in Munich, is a one-hundred-per-cent subsidiary of Celgene Corporation, based in New Jersey, USA. In recent years, Celgene has re-invested between 25 and 35 per cent of its revenue in research and development. These figures are above the average of the industry. According to our company philosophy, innovation is the key to success.

The company’s scientific and, as a result, economic success is based on its analytical capacities and the excellent knowledge of its workforce. Work at Celgene is reflecting the scientific or medical educational background of 80 per cent of all employees. Knowledge is the foundation of our future success. This is why Celgene supports educational offers for children inside and outside school as one way of returning some of the company’s business success.